<DOC>
	<DOCNO>NCT02674776</DOCNO>
	<brief_summary>This study multi-center , double-blind , randomize , parallel control trial . Patients acute gout enrol randomly allocate 2 group : HuZhen capsule treatment group Placebo control group . Randomization code establish biostatistician . Observe follow 3 day ( 72 hour ) onset . Change VAS score baseline , proportion improvement damp-heat retention , change C-reactive protein ( CRP ) erythrocyte sedimentation rate ( ESR ) baseline , change white blood cell count whole blood cell analysis baseline , number adverse event monitor compare group .</brief_summary>
	<brief_title>Efficacy Safety HuZhen Capsule Treatment Patients With Acute Gout</brief_title>
	<detailed_description>The test group give HuZhen capsule 1.6g three time per day , control group give placebo 1.6g three time per day . The invention last 3 day .</detailed_description>
	<mesh_term>Gout</mesh_term>
	<criteria>1 . Score equal large 40cm 0100cm VAS pain scale . 2 . Acute attack gout longer 2 day . 3 . Participant acute gout diagnose `` dampheat retention '' Traditional Chinese medicine . 4 . Age 1865 year informed consent . 1 . Chronic gouty arthritis . 2 . Pseudogout , acute rheumatic fever suppurative arthritis , traumatic arthritis , erysipelas , meander rheumatism arthritis . 3 . Antiinflammatory medication treatment acute gout . 4 . Pregnant breastfeed woman . 5 . History severe allergy , include diclofenac sodium . 6 . Serum creatinine high upper normal limit . ALT AST high upper normal limit two time . 7 . Fever ( T &gt; 38.5 â„ƒ )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>